These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 37511802)

  • 1. An Overview of Cefiderocol's Therapeutic Potential and Underlying Resistance Mechanisms.
    Domingues S; Lima T; Saavedra MJ; Da Silva GJ
    Life (Basel); 2023 Jun; 13(7):. PubMed ID: 37511802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Perspectives on Antimicrobial Agents: Cefiderocol.
    McCreary EK; Heil EL; Tamma PD
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0217120. PubMed ID: 34031052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
    Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
    Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Discovery of a New Siderophore Cephalosporin, Cefiderocol].
    Yamano Y
    Yakugaku Zasshi; 2024; 144(6):627-631. PubMed ID: 38825471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of Cefiderocol Against
    Iregui A; Khan Z; Landman D; Quale J
    Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cefiderocol: a novel siderophore cephalosporin against multi-drug resistant Gram-negative bacilli infections].
    Kuai J; Wang X; Wang H
    Sheng Wu Gong Cheng Xue Bao; 2022 Mar; 38(3):990-1003. PubMed ID: 35355469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.
    Kollef M; Dupont H; Greenberg DE; Viale P; Echols R; Yamano Y; Nicolau DP
    Int J Antimicrob Agents; 2023 Aug; 62(2):106882. PubMed ID: 37301312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compassionate use of cefiderocol for carbapenem-resistant
    Mabayoje DA; NicFhogartaigh C; Cherian BP; Tan MGM; Wareham DW
    JAC Antimicrob Resist; 2021 Jun; 3(Suppl 1):i21-i24. PubMed ID: 34223152
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Mushtaq S; Sadouki Z; Vickers A; Livermore DM; Woodford N
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of carbapenem-resistant
    Canton R; Doi Y; Simner PJ
    Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1077-1094. PubMed ID: 35502603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.
    Ong'uti S; Czech M; Robilotti E; Holubar M
    Clin Infect Dis; 2022 Apr; 74(7):1303-1312. PubMed ID: 34492098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
    Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
    J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections.
    Drwiega EN; Griffith NC; Danziger LH
    Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):245-259. PubMed ID: 35594628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint.
    Massol J; Dinh A; Jeannot K; Duran C; Bouchand F; Potron A; Dortet L; Jehl F
    J Glob Antimicrob Resist; 2024 Jun; 38():140-145. PubMed ID: 38844258
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Longshaw C; Manissero D; Tsuji M; Echols R; Yamano Y
    JAC Antimicrob Resist; 2020 Sep; 2(3):dlaa060. PubMed ID: 34223017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefiderocol: A Siderophore Cephalosporin.
    El-Lababidi RM; Rizk JG
    Ann Pharmacother; 2020 Dec; 54(12):1215-1231. PubMed ID: 32522005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant
    Karruli A; Migliaccio A; Pournaras S; Durante-Mangoni E; Zarrilli R
    Antibiotics (Basel); 2023 Dec; 12(12):. PubMed ID: 38136764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.
    Monogue ML; Tsuji M; Yamano Y; Echols R; Nicolau DP
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against
    Carcione D; Siracusa C; Sulejmani A; Migliavacca R; Mercato A; Piazza A; Principe L; Clementi N; Mancini N; Leoni V; Intra J
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.